

Evoke Neuroscience to present at OCTANe's 13th Annual Medical Technology Innovation Forum

NEW YORK, NY, USA, October 11, 2018 /EINPresswire.com/ -- [Evoke Neuroscience](#) announces it has been selected to present to the attendees of this year's Medical Technology Innovation Forum on October 29th in Newport Beach, California.

Evoke will present its eVox® System, which aids physicians in the diagnosis of memory loss and other cognitive disorders, to a diverse group of clinicians, investors and healthcare industry professionals.

Evoke has assembled an executive team of industry veterans and innovators to lead the research, development and commercialization of its next generation technology.



As of October 4th, 2018, Marinela Gomboshev has been promoted to the position of Chief Executive Officer, bringing expertise in medical device operations, product development, marketing and commercialization. Marinela has been EVP of Operations and Marketing at Evoke for four years. Co-founder and Chief Innovation Officer, James Thompson, Ph.D., will continue to ensure that Evoke's technology is grounded in scientific validity and is maximizing clinical utility for physicians. Peter E. Raymond will lead the company's next generation research and development as Chief Research and Development Officer. Peter E. Raymond has been named an IBM Global Platinum Entrepreneur for his work in Cognitive Artificial Intelligence (AI), developed the world's first biometric heart failure simulator, and has been featured by Apple for innovation in healthcare. Co-founder and former Chief Executive Officer, David Hagedorn, Ph.D., will remain on the Evoke Neuroscience Board of Directors.

"To date, our eVox System has been used to measure the brain health of over 45,000 patients in primary care clinics and specialty practice settings in the United States." said Marinela Gomboshev, Chief Executive Officer at Evoke Neuroscience. "Our eVox platform presents a solid foundation for future development to aid doctors in the diagnosis of cognitive diseases such as dementia."

Historically, most providers have relied on self-report questionnaires and effort-based computerized testing for determining a diagnosis. But to understand cognitive health, and more specifically memory, it is important to measure key biomarkers of the brain itself. The eVox® System delivers objective and stable biomarkers that may aid in diagnosis.

Primary and specialty care physicians can use eVox® to acquire these biomarkers, in-office, via a non-invasive procedure performed with minimal staff training and time. Doctors should use

their professional judgment in determining when the eVox® System is appropriate to aid in diagnosis.

About Medical Technology Innovation Forum

OCTANe's 13th Annual Medical Technology Innovation Forum (MTIF) is the largest conference in Southern California focused on high-growth medical technology innovation and investment. The collaboration of OCTANe, LaunchPad™, and the Orange County/Inland Empire SBDC Network has enabled hundreds of life science technology, information technology, sports technology, and clean technology companies to get started and grow. Since 2008, LaunchPad SBDC companies have obtained \$1.4 billion of investment capital infusion.

About Evoke Neuroscience

Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox® System to acquire objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as dementia. Evoke was named one of the INC. 500/5000 fastest growing companies two years in a row.

Morgan Ingemanson

Evoke Neuroscience

9172616096

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.